Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2007

01-01-2007 | Epidemiology

Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM)

Authors: Carlos Jara Sánchez, Amparo Ruiz, Miguel Martín, Antonio Antón, Blanca Munárriz, Arrate Plazaola, José Schneider, Purificación Martínez del Prado, Emilio Alba, Antonio Fernández-Aramburo

Published in: Breast Cancer Research and Treatment | Issue 2/2007

Login to get access
Metadata
Title
Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM)
Authors
Carlos Jara Sánchez
Amparo Ruiz
Miguel Martín
Antonio Antón
Blanca Munárriz
Arrate Plazaola
José Schneider
Purificación Martínez del Prado
Emilio Alba
Antonio Fernández-Aramburo
Publication date
01-01-2007
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9282-0

Other articles of this Issue 2/2007

Breast Cancer Research and Treatment 2/2007 Go to the issue

Preclinical Study

Lewis x Antigen Mediates Adhesion of Human Breast Carcinoma Cells to Activated Endothelium. Possible Involvement of the Endothelial Scavenger Receptor C-type Lectin

Letter to the Editor

COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic for molecular markers

Clinical Trial

Aromatase inhibitors reverse tamoxifen induced endometrial ultrasonographic changes in postmenopausal breast cancer patients

Epidemiology

NSAID use and survival after breast cancer diagnosis in post-menopausal women

Preclinical Study

Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells

Preclinical Study

Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits